Protocol of the Cologne Corona Surveillance (CoCoS) Study- a prospective population-based cohort study.
COVID-19
Coronavirus
Pandemic
Risk behaviours
Rolling cohort
Socio-economic factors
Surveillance
Journal
BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562
Informations de publication
Date de publication:
02 07 2021
02 07 2021
Historique:
received:
29
05
2021
accepted:
03
06
2021
entrez:
3
7
2021
pubmed:
4
7
2021
medline:
9
7
2021
Statut:
epublish
Résumé
Surveillance strategies are critical to cope with the current SARS-CoV-2 pandemic and to evaluate, as well as adjust government-imposed countermeasures. Incidence estimates are widely based on laboratory confirmed cases reported by health authorities. Prevalence and incidence data of SARS-CoV-2 is still scarce, along with demographic and behavioural factors associated with infection risk. The Cologne Corona Surveillance Study will be conducted in the City of Cologne, which is the fourth-largest city in Germany with a population of approximately 1.1 million. Researchers will apply self-sampling surveillance to a rolling cohort of Cologne residents. Random samples of 6000 Cologne residents 18 years of age and older will be drawn from the registration office. Upon receiving the information and saliva sample kit, participants will be asked to fill out a questionnaire online or via phone, sign written informed consent, and send back written consent, as well as saliva sample. The saliva samples will be tested for SARS-CoV-2 by reverse PCR. The questionnaire will be administered to gather information about personal characteristics such as health status and risks. A second round of testing will take place 6 weeks after the first. Self-administered saliva sampling proved to be a legitimate and feasible alternative to nasopharyngeal swabs taken by health professionals. However, it is unclear whether the targeted response rate of 40% can be achieved and whether the results are representative of the population. DRKS.de, German Clinical Trials Register (DRKS), Identifier: DRKS00024046 , Registered on 25 February 2021.
Sections du résumé
BACKGROUND
Surveillance strategies are critical to cope with the current SARS-CoV-2 pandemic and to evaluate, as well as adjust government-imposed countermeasures. Incidence estimates are widely based on laboratory confirmed cases reported by health authorities. Prevalence and incidence data of SARS-CoV-2 is still scarce, along with demographic and behavioural factors associated with infection risk.
METHODS
The Cologne Corona Surveillance Study will be conducted in the City of Cologne, which is the fourth-largest city in Germany with a population of approximately 1.1 million. Researchers will apply self-sampling surveillance to a rolling cohort of Cologne residents. Random samples of 6000 Cologne residents 18 years of age and older will be drawn from the registration office. Upon receiving the information and saliva sample kit, participants will be asked to fill out a questionnaire online or via phone, sign written informed consent, and send back written consent, as well as saliva sample. The saliva samples will be tested for SARS-CoV-2 by reverse PCR. The questionnaire will be administered to gather information about personal characteristics such as health status and risks. A second round of testing will take place 6 weeks after the first.
DISCUSSION
Self-administered saliva sampling proved to be a legitimate and feasible alternative to nasopharyngeal swabs taken by health professionals. However, it is unclear whether the targeted response rate of 40% can be achieved and whether the results are representative of the population.
TRIAL REGISTRATION
DRKS.de, German Clinical Trials Register (DRKS), Identifier: DRKS00024046 , Registered on 25 February 2021.
Identifiants
pubmed: 34215236
doi: 10.1186/s12889-021-11206-9
pii: 10.1186/s12889-021-11206-9
pmc: PMC8253235
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1295Subventions
Organisme : Bundesministerium für Bildung und Forschung
ID : 01KX2021
Références
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
JMIR Public Health Surveill. 2020 Apr 2;6(2):e18606
pubmed: 32240095
BMC Public Health. 2020 Jun 30;20(1):1036
pubmed: 32605549
Front Public Health. 2020 May 29;8:241
pubmed: 32574307
Nat Commun. 2021 Apr 9;12(1):2117
pubmed: 33837204
Proc Natl Acad Sci U S A. 2020 Jul 7;117(27):15530-15535
pubmed: 32554604
Dtsch Arztebl Int. 2020 Dec 11;117(50):861-867
pubmed: 33295275
Lancet Infect Dis. 2021 Apr 12;:
pubmed: 33857405